Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies

RATIONALE & OBJECTIVE: Tolvaptan is indicated for treatment of patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Participants aged 56-65 years constituted a small proportion of the Replicating Evidence of Preserved Renal Function: an Investigation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chebib, Fouad T., Zhou, Xiaolei, Garbinsky, Diana, Davenport, Eric, Nunna, Sasikiran, Oberdhan, Dorothee, Fernandes, Ancilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220412/
https://www.ncbi.nlm.nih.gov/pubmed/37250503
http://dx.doi.org/10.1016/j.xkme.2023.100639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220412/
https://www.ncbi.nlm.nih.gov/pubmed/37250503
http://dx.doi.org/10.1016/j.xkme.2023.100639

Ejemplares similares